Austin, Texas, May 15, 2018 (BUSINESS WIRE) - Elligo Health Research, which improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients, has launched a Research Ready™ program for physician practices interested in becoming a study site. Through the program, health care providers are able to offer clinical research studies as a care option to their patients. As a result, patient participation and retention rates increase, contributing to a more diverse population of patients and subsequently enabling clinical research organizations (CROs) and sponsors to get their studies up and running faster. The Research Ready™ program is part of Elligo’s Goes Direct™ approach, which provides a larger patient pool, more randomizations and better retention by making clinical research studies accessible to physicians and their patients. Through the program, physician practices are evaluated on a number of study-related components and are provided the technology, the infrastructure and a clinical coordinator to perform trials. “We know patient diversification is important for our trial sponsors and CROs,” said John Potthoff, Ph.D., CEO of Elligo. “We make it easier for more patients to participate in trials through their own trusted physician. And, not only are our sites benefiting from the infrastructure support, but our sponsors and CROs are getting quality study data from community practice researchers.” Every research site conducting research with Elligo has received the Research Ready™ designation. Currently, Elligo has more than 200 physician partners - with specialization in women’s health, gastroenterology, urology and pain management indications. About Elligo Health ResearchElligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct™ approach uses state-of-the-art elliGO DIRECT™ technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com. CONTACT: Lea Studer SCORR Marketing 402.366.1752
lea@scorrmarketing.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.